GlaxoSmithKline shoots for combo attack against melanoma in surgery patients

Melanoma under a microscope--Image courtesy of NIH GlaxoSmithKline ($GSK) has stepped up its late-stage program to advance a combo of targeted cancer drugs against deadly skin cancer, with a new study to see whether its experimental BRAF and MEK inhibitors can keep melanoma from coming back after surgeries. The London-based drug giant said that the late-stage "COMBI-AD" study tests its...